FM - Artigos publicados em periódicos

URI Permanente para esta coleção

http://200.137.215.59//handle/ri/1408

Navegar

Navegando FM - Artigos publicados em periódicos por Autor "Abud, Murilo Batista"

Agora exibindo 1 - 4 de 4
  • Imagem de Miniatura
    Item
    Alterações retinianas apresentadas em pacientes portadores de hemoglobinopatia falciforme atendidos em um serviço universitário de oftalmologia
    (2011) Freitas, Luiz Guilherme Azevedo de; Isaac, David Leonardo Cruvinel; Tannure, William Tomaz; Lima, Elisa Vieira da Silva; Abud, Murilo Batista; Tavares, Renato Sampaio; Freitas Neto, Clovis Arcoverde de; Ávila, Marcos Pereira de
    Purpose: To identify retinal manifestations in patients with sickle cell disease referred to a reference eye hospital in Goiânia (GO). Methods: Ophthalmic evaluation was made in 50 patients (100 eyes) with sickle cell disease to evaluate the most common manifestations of this group. Results: Hemoglobinopathy SS was the most commonly found, followed by hemoglobin SC, AS and Stahl. Twenty-two percent of the patients had retinal changes, of these 73% were male. Retinal changes observed were: “sea fan”, “black sunburst”, vitreous hemorrhage, and retinal detachment. In the classification of retinopathy, 73% had proliferative form, seen in the types AS and SC and 27% had non-proliferative retinopathy, seen in patients with SS type. Conclusions: We observed a large numbers of patients with retinal changes, most of them with hemoglobinopathy SC, followed by AS and SS groups. The proliferative changes were the most commonly observed. Vitreous hemorrhage and retinal detachment were the most prevalent manifestations in proliferative retinopathy and showed to be more common in patients with SC hemoglobinopathy in the studied population.
  • Imagem de Miniatura
    Item
    Comparação do efeito analgésico entre etoricoxib 90 mg e dipirona sódica na exérese de pterígio primário com transplante autólogo de conjuntiva
    (2009) Frantz, Kariza Aiko; Moura Filho, Edney de Resende; Abud, Murilo Batista; Ávila, Marcos Pereira de; Silva, Leopoldo Magacho dos Santos
    Purpose: To compare the analgesic effect between dipyrone, 90 mg etoricoxib, and placebo after excision of primary ptery- gium with conjunctival autograft. Methods: Prospective, ran- domized, double-masked clinical trial. Three groups of 26 pa- tients (one eye per patient) were submitted to surgery and re- ceived the study drugs for five days after surgery. A scale of pain was used, graduated from zero to ten, for patient evalua- tion in the first, third and fifth postoperative days. The pain was classified as absent (zero), mild (1 to 3), moderate (4 to 7) and severe (8 to 10). Statistical analysis was performed with the SPSS, version 11.5. Results: A statistically significant dif- ference was found between etoricoxib and dipyrone in the first and third postoperative days (p=0.001 and p=0.01; respecti- vely). Etoricoxib was superior to placebo only in the first pos- toperative day (p=0.04). There was no significance in the com- parison between dipyrone and placebo. Conclusions: Anal- gesia of etoricoxib was superior to placebo in the first pos- toperative day and to dipyrone in the third and fifth days after excision of primary pterygium with conjunctival autograft. There was no significant difference between dipyrone and placebo in all time points.
  • Imagem de Miniatura
    Item
    Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double- blind study
    (2012) Isaac, David Leonardo Cruvinel; Abud, Murilo Batista; Frantz, Kariza Aiko; Rassi, Alan Ricardo; Ávila, Marcos Pereira de
    Purpose: To compare the effect of a single intravitreal injection of triamcinolone acetonide and bevacizumab in reducing macular thickness, which was measured by optical coherence tomography (OCT) in patients with diabetic macular oedema (DMO). Methods: The patients received a single intravitreal injection of 1.25 mg bev- acizumab in one randomly selected eye and 4.0 mg triamcinolone acetonide in the contralateral eye. Central foveal thickness measurement (CFT) with OCT was taken at the initial visit and at the 4-week, 12-week and 24-week visits. Results: Eleven patients (22 eyes) were enrolled and statistically analysed. CFT reduced in the eyes treated with triamcinolone and those treated with bevacizumab in weeks 4 and 12 (p < 0.05). At the 24-week follow-up, no significant difference was noted, relative to the initial visit. Comparing the two groups treated with dif- ferent drugs, a statistically significant difference in CFT in weeks 4 and 12 was noted, with a more significant reduction in triamcinolone-treated eyes (p < 0.05). Regarding visual acuity (VA), patients treated with triamcinolone had improvement in VA at 4-week (p = 0.02) and 12-week follow-up (p = 0.01), while the group treated with bevacizumab had VA improvement at 4 -week follow-up (p = 0.02). Among the eyes treated with triamcinolone, intraocular pressure (IOP) measure- ment of more than 21 mmHg was found in three eyes (27.3%). Conclusions: Intravitreal triamcinolone proved to be more efficient in reducing DMO, providing longer lasting visual improvement, relative to bevacizumab. Eyes treated with triamcinolone had the highest percentage increase in IOP. Further studies are needed to corroborate these findings.
  • Imagem de Miniatura
    Item
    Estudo de toxicidade retiniana após injeções intravítreas seriadas de infliximabe em olhos de coelhos
    (2011) Rassi, Alan Ricardo; Rigueiro, Moacyr Pezati; Isaac, David Leonardo Cruvinel; Dourado, Leticia Barbosa Kawano; Abud, Murilo Batista; Freitas, Ericka Campos; Carneiro, Luciana Barbosa; Ávila, Marcos Pereira de
    Purpose: To determine retinal and choroid toxicity levels of two and three infliximab intravitreous injections in albino rabbits by means of electroretinographic, histological and ophthalmological clinical tests. Methods: 12 albino rabbits were used in the study. Each eye was given two (n=10 eyes) or three (n=10 eyes) serial intravitreous 2 mg infliximab injections dissolved in 0.06 ml of saline, at monthly intervals. A separate group of rabbits (n=4 eyes) served as a control group. Ninety days after the study had begun, the rabbits underwent clinical and electro- retinographic tests, and after being enucleated, the eyes were examined for histological changes. Results: Slit-lamp biomicroscopy and fundoscopic examination did not reveal any significant retinal abnormalities in the eyes injected with infliximab and control eyes or in pre- and post-treated eyes. The histological change that was noted was the presence of rare lymphocytes and eosinophils in the posterior vitreous of some of the rabbits subjected to two or three injections, but it was not considered clinically significant. A severe inflammatory reaction with vitreous exudates and ganglion cell edema in a single rabbit was clinically significant. The electroretinographic tests showed amplitudes that were on the average 12-13% smaller than those obtained before the treatment, however, there were no statistically significant differences when comparing the amplitude or the implicit time between pre- and post-treatment electroretinographic findings. Conclusion: Two and three intravitreous 2 mg infliximab injections in rabbits at monthly intervals did not cause any changes after a 90-day follow-up, according to histological and electroretinographic tests and after clinical evaluation. Differently from prior studies that have investigated potential retinotoxicity effects after single administrations, this study investigated the possibility of retinotoxicity after multiple injections. Clinical studies in humans should be conducted to better evaluate the safety of this drug in the treatment of certain diseases affecting the retina and the choroid.